Welcome to the international HTA database

Showing [23731 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2027	Norwegian Medical Products Agency (NOMA)	[Wearable cardioverter defibrillator (LifeVest) for people with high risk of sudden cardiac arrest: a single technology assessment]
2027	Belgian Health Care Knowledge Centre (KCE)	Review of new oncology indications for the use of positron emission tomography (PET-scans) (Study 2024-12)
2026	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Barriers and facilitators when implementing guidelines in health and social care for the elderly]
2026	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effectiveness evaluation of Nirmatrelvir plus ritonavir (Paxlovid)]
2026	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Review of the lower age limit and frequency of early-detection colonoscopy in the colorectal cancer screening programme]
2026	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Acupuncture for migraine prophylaxis]
2026	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Newborn screening for metachromatic leukodystrophy]
2026	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[X-ray image of the lung: Can artificial intelligence support the analysis of X-ray images?]
2026	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Quality of sleep: Can taking melatonin as a dietary supplement, e.g. in the form of tablets, sprays or soft gums, help to improve sleep?]
2026	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Reinforced foster homes]
2025	Austrian Institute for Health Technology Assessment (AIHTA)	Exagamglogene autotemcel (Exa-cel, Casgevy®)
2025	NIHR Health Technology Assessment programme	Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Appropriate use of cardiac monitoring in the emergency department]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Prediction models in dental care - basis for the National Board of Health and Welfare’s mission to develop a national model for risk assessment in dental care]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[ADHD and driving performance]
2025	Health Sciences Institute in Aragon (IACS)	Programme for the use of real world data in health technology assessment: using real-world data for health technology assessment
2025	Penn Medicine Center for Evidence-based Practice (CEP)	Dedicated staff for placement of indwelling urinary catheters
2025	NIHR Health Technology Assessment programme	The acceptability of blood spot screening and genome sequencing in newborn screening: a systematic review examining evidence and frameworks
2025	NIHR Health Technology Assessment programme	Management of diarrhoea in patients with stable ulcerative colitis with low FODMAP diet, amitriptyline, ondansetron or loperamide: the MODULATE RCT
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Bispecific and tumor-infiltrating T cell therapies: considerations for deployment in Quebec]
2025	Gesundheit Osterreich GmbH (GOeG)	[Efficacy and safety of antibody therapies in early-stage Alzheimer's disease]
2025	NIHR Health Services and Delivery Research programme	The implementation of safety management systems in healthcare: a systematic review and international comparison
2025	Scottish Health Technologies Group (SHTG)	Stability of prostate specific antigen (PSA) in blood samples
2025	Scottish Health Technologies Group (SHTG)	Artificial intelligence (AI) assisted endoscopy
2025	Scottish Health Technologies Group (SHTG)	Vacuum bell device for people with pectus excavatum
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Effectiveness and safety of scalp cooling to prevent chemotherapy-induced alopecia (CIA)]
2025	National Institute for Health and Care Excellence (NICE)	Intravascular lithotripsy to treat calcified coronary arteries during percutaneous coronary intervention. NICE interventional procedures guidance 802
2025	National Institute for Health and Care Excellence (NICE)	Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment. NICE technology appraisal guidance 1036
2025	National Institute for Health and Care Excellence (NICE)	Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 1037
2025	National Institute for Health and Care Excellence (NICE)	Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy. NICE technology appraisal guidance 1040
2025	National Institute for Health and Care Excellence (NICE)	Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over. NICE technology appraisal guidance 1039
2025	National Institute for Health and Care Excellence (NICE)	Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over. NICE technology appraisal guidance 1038
2025	National Institute for Health and Care Excellence (NICE)	Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over. NICE technology appraisal guidance 1033
2025	National Institute for Health and Care Excellence (NICE)	Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1042
2025	National Institute for Health and Care Excellence (NICE)	Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer. NICE technology appraisal guidance 1041
2025	National Institute for Health and Care Excellence (NICE)	Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over. NICE technology appraisal guidance 1044
2025	National Institute for Health and Care Excellence (NICE)	Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. NICE technology appraisal guidance 1043
2025	NIHR Health Technology Assessment programme	Understanding the effectiveness and underlying mechanisms of lifestyle modification interventions in adults with learning disabilities: a mixed-methods systematic review
2025	NIHR Health Services and Delivery Research programme	Optimisation of the deployment of automated external defibrillators in public places in England
2025	NIHR Health Services and Delivery Research programme	Clinical and cost-effectiveness of paramedics working in general practice: a mixed-methods realist evaluation
2025	NIHR Health Technology Assessment programme	Establishing palliative care research partnerships in Northern Ireland
2025	NIHR Health Technology Assessment programme	Learnings from the establishment and delivery of the UK Collaborative Paediatric Palliative Care Research Network
2025	NIHR Health Technology Assessment programme	Interventions that challenge established and accepted clinical practice: lessons learnt from a process evaluation of the STOP-APE trial
2025	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effectiveness evaluation of Ritlecitinib tosylate (Litfulo)]
2025	NIHR Health Services and Delivery Research programme	Cancer in English prisons: a mixed-methods study of diagnosis, treatment, care costs and patient and staff experiences
2025	NIHR Health Services and Delivery Research programme	Understanding and addressing factors affecting carers’ mental health during end-of-life caregiving: synopsis of meta synthesis of literature and stakeholder collaboration
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Confirmed trichomonas vaginalis infection: pharmacological treatment]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Lung cancer treatment algorithm]
2025	NIHR Health Services and Delivery Research programme	Intersecting factors of disadvantage and discrimination and their effect on daily life during the coronavirus pandemic: the CICADA-ME mixed-methods study
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Breast cancer treatment algorithm]
2025	NIHR Health Technology Assessment programme	Stepping into day treatment approach versus inpatient treatment for adults with anorexia nervosa: the DAISIES RCT
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Tumor biomarkers related to managing people with prostate cancer]
2025	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effectiveness evaluation of the aortic stent graft (The GORE TAG Conformable Thoracic Stent Graft with ACTIVE CONTROL System) for thoracic aortic aneurysm and complicated type B aortic dissection]
2025	NIHR Health Services and Delivery Research programme	Improving the experience of health services for trans and gender-diverse young people and their families: an exploratory qualitative study
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Endovascular implantation of a transcatheter tricuspid valve replacement for tricuspid valve insufficiency – Second addendum to Project H23-03]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Meropenem/vaborbactam (bacterial infections, several therapeutic indications) - Assessment in accordance with § 35a (1c) Social Code Book (SGB) V ]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Zolbetuximab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-negative) – Assessment in accordance with § 35a Social Code Book (SGB) V (1), Sentence 11]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Elafibranor (primary biliary cholangitis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Epcoritamab (DLBCL, third line) - Benefit assessment according to §35a Social Code Book V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Delgocitinib (moderate to severe chronic hand eczema) – Benefit assessment according to §35a Social Code Book V]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Tumor biomarkers related to managing people with cervical cancer]
2025	NIHR Health Services and Delivery Research programme	Peer support for adult social care in prisons in England and Wales: a mixed-methods rapid evaluation
2025	NIHR Health Technology Assessment programme	Multi-cancer early detection tests for general population screening: a systematic literature review
2025	NIHR Health Technology Assessment programme	Development of a clinical decision support tool for Primary care Management of lower Urinary tract Symptoms in men: the PriMUS study
2025	National Institute for Health and Care Excellence (NICE)	Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia. NICE interventional procedures guidance 798
2025	National Institute for Health and Care Excellence (NICE)	Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adults. NICE interventional procedures guidance 799
2025	National Institute for Health and Care Excellence (NICE)	Tebentafusp for treating advanced uveal melanoma. NICE technology appraisal guidance 1027
2025	National Institute for Health and Care Excellence (NICE)	Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer. NICE technology appraisal guidance 1030
2025	National Institute for Health and Care Excellence (NICE)	Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal). NICE technology appraisal guidance 1029
2025	National Institute for Health and Care Excellence (NICE)	Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal). NICE technology appraisal guidance 1028
2025	National Institute for Health and Care Excellence (NICE)	Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over. NICE technology appraisal guidance 1031
2025	National Institute for Health and Care Excellence (NICE)	Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours. NICE technology appraisal guidance 1034
2025	National Institute for Health and Care Excellence (NICE)	Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal). NICE technology appraisal guidance 1032
2025	National Institute for Health and Care Excellence (NICE)	Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease. NICE technology appraisal guidance 1035
2025	NIHR Health Technology Assessment programme	Public and patient involvement (PPI) in the design, execution and dissemination of a trial: the BISTRO trial
2025	NIHR Health Technology Assessment programme	A systematic review of the cost-effectiveness of anti-VEGF drugs for the treatment of diabetic retinopathy
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Microinvasive glaucoma surgery (MIGS) - Hydrus Microstent for the treatment of mild to moderate glaucoma]
2025	NIHR Health and Social Care Delivery Program	Systematic review of integrated mental and physical health services for children and young people with eating and functional symptoms
2025	Belgian Health Care Knowledge Centre (KCE)	Cost-effectiveness of maternal immunisation by Abrysvo® or a single injection of a monoclonal antibody (Beyfortus®) in infants for infant protection against infection by the respiratory syncytial virus in Belgium (Study 2024-51)
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – benefit assessment according to §35a Social Code Book V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis for the update of the DMP “type 2 diabetes”]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Phonocardiography to rule out coronary heart disease]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Development of a decision aid for carotid revascularization surgery for carotid stenosis]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Pharmacological treatment of polycystic ovary syndrome - health and quality of life in the short and long term]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Interventions for behavioural change in the aim of promoting health and preventing disability in the elderly]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Psychometric properties for instruments used to measure core outcomes for provoked vestibulodynia]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Accuracy of diagnostic algorithms for suspected or elevated risk of ovarian cancer]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Newborn screening for Metachromatic leukodystrophy (MLD)]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Interventions to formal caregivers for increased patient safety]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Digital technology promoting health for children and adolescents]
2025	The Danish Health Technology Council (DHTC)	[Assessment of treatment of knee pain]
2025	The Danish Health Technology Council (DHTC)	[Assessment of forearm fractures in children]
2025	The Danish Health Technology Council (DHTC)	[Assessment of point-of-care tests for use at home for elderly patients]
2025	The Danish Health Technology Council (DHTC)	[Assessment of HAL-assisted TUR-BT]
2025	The Danish Health Technology Council (DHTC)	[Assessment of SelfBack App for lower back pain]
2025	The Danish Health Technology Council (DHTC)	[Assessment of supervised gait training]
2025	The Danish Health Technology Council (DHTC)	[Assessment of Merlin Assay for diagnosis of malignant melanoma]
2025	The Danish Health Technology Council (DHTC)	[Assessment of percutaneous vertebroplasty (PVP) for compression fractures]
2025	The Danish Health Technology Council (DHTC)	[Assessment of endovascular aortic repair (EVAR)]
2025	Swiss Federal Office of Public Health (FOPH)	Betahistine or cinnarizine with or without dimenhydrinate for Ménière’s disease/syndrome and symptoms of vestibular vertigo and/or tinnitus